US FDA designates PYC's lead as a fast track development program

11 August 2023 - The Company is currently evaluating the safety/tolerability and efficacy of an investigational drug candidate with disease-modifying potential ...

Read more →

PYC Therapeutics gets fast track status from FDA for retinitis pigmentosa treatment

1 August 2023 - PYC Therapeutics has received fast track designation from the US FDA for a new drug aimed ...

Read more →

FDA grants fast track designation to IVS-3001, a CAR-T cell therapy in the treatment of renal cell carcinoma

31 July 2023 - Invectys is pleased to announce the US FDA has granted fast track designation to its revolutionary ...

Read more →

Astria Therapeutics receives fast track designation for STAR-0215 for the treatment of hereditary angioedema

20 July 2023 - On track for proof of concept results in HAE patients in mid 2024. ...

Read more →

Excision BioTherapeutics receives FDA fast track designation for EBT-101, a first in class CRISPR based gene therapy candidate to functionally cure HIV-1

20 July 2023 - EBT-101 is a potentially curative, one time CRISPR based treatment which makes two cuts in integrated retroviral ...

Read more →

FDA grants fast track designation for Ambrx’s ARX517 for the treatment of metastatic castration resistant prostate cancer

19 July 2023 - Ambrx Biopharma today announced that the US FDA has granted fast track designation to Ambrx’s proprietary anti-PSMA ...

Read more →

Karyopharm receives FDA fast track designation for selinexor for the treatment of myelofibrosis

17 July 2023 - Regulatory designation includes primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis. ...

Read more →

Biosyngen's first in class cell therapy BRG01 receives FDA fast track designation

12 July 2023 -  On July 6, 2023, Biosyngen received an official notification from the US FDA granting fast track ...

Read more →

Synlogic granted fast track designation from FDA for labafenogene marselecobac (SYNB1934) for treatment of phenylketonuria

11 July 2023 - Synlogic today announced that the US FDA has granted fast track designation to labafenogene marselecobac (previously known ...

Read more →

Kazia's paxalisib receives fast track designation from FDA for treatment of solid tumour brain metastases harbouring PI3K pathway mutations in combination with radiation therapy

6 July 2023 - Kazia Therapeutics is pleased to announce that its lead program, paxalisib, has been awarded fast track ...

Read more →

Genprex receives US FDA fast track designation for Reqorsa immunogene therapy in combination with Tecentriq for the treatment of small cell lung cancer

28 June 2023 - Third FDA fast track designation further validates the potential of Reqorsa. ...

Read more →

AC Immune receives FDA fast track designation for anti-amyloid beta active immunotherapy, ACI-24.060, to treat Alzheimer’s disease

27 June 2023 - Initial PET data on amyloid plaque reduction in Alzheimer's disease expected H1, 2024. ...

Read more →

GSK receives US FDA fast track designation for investigational vaccine against gonorrhoea

27 June 2023 - Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to ...

Read more →

Cidara Therapeutics receives US FDA fast track designation for CD388, a novel drug-FC conjugate targeting influenza A and B

22 June 2023 - Cidara Therapeutics today announced that the US FDA has granted fast track designation to CD388, Cidara’s novel ...

Read more →

Teikoku Pharma granted FDA fast track designation for TPU-006, a novel 4 day dexmedetomidine transdermal system for post operative pain management

21 June 2023 - Teikoku Pharma today announced that the US FDA granted fast track designation for TPU-006 in managing post-operative ...

Read more →